Safety

News

As IARC uprates talc cancer risk, will J&J be affected?

The International Agency for Research on Cancer (IARC) has published a new assessment of talc’s potential to cause cancer, concluding that is it ‘probably carcinogenic’ to humans.

News

Study links Ozempic/Wegovy to sight-threatening disorder

Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.

News

NWEH says module cuts side effect reporting burden in trials

Monitoring patient safety is of the utmost importance when running a clinical trial, but recording and reporting side effects can be labour-intensive and costly.

News

Study finds low secondary cancer risk with CAR-Ts

There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.

R&D

Advancing innovation in life sciences R&D and Quality: Towar...

This year’s Veeva R&D and Quality Summit saw full-house attendance at the Marriott Auditorium Hotel in Madrid.

News

Pfizer pauses DMD gene therapy trial after boy’s death

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus